1.35 USD
-0.08 (-5.59%)
1.4 USD
+0.05 (+3.7%)
Overall CHRS gets a fundamental rating of 2 out of 10. We evaluated CHRS against 531 industry peers in the Biotechnology industry. Both the profitability and financial health of CHRS have multiple concerns. CHRS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CHRS has reported negative net income.
CHRS had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CHRS reported negative net income in multiple years.
In the past 5 years CHRS reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 30.00%, CHRS belongs to the top of the industry, outperforming 98.12% of the companies in the same industry.
With an excellent Return On Equity value of 176.56%, CHRS belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30% | ||
| ROE | 176.56% | ||
| ROIC | N/A |
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of CHRS (185.44%) is better than 98.87% of its industry peers.
In the last couple of years the Profit Margin of CHRS has declined.
CHRS's Gross Margin of 47.79% is fine compared to the rest of the industry. CHRS outperforms 74.95% of its industry peers.
In the last couple of years the Gross Margin of CHRS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 185.44% | ||
| GM | 47.79% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
2. Health
2.1 Basic Checks
CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CHRS has more shares outstanding
The number of shares outstanding for CHRS has been increased compared to 5 years ago.
The debt/assets ratio for CHRS has been reduced compared to a year ago.
2.2 Solvency
CHRS has an Altman-Z score of -4.13. This is a bad value and indicates that CHRS is not financially healthy and even has some risk of bankruptcy.
CHRS's Altman-Z score of -4.13 is in line compared to the rest of the industry. CHRS outperforms 40.11% of its industry peers.
CHRS has a Debt/Equity ratio of 0.58. This is a neutral value indicating CHRS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.58, CHRS is not doing good in the industry: 73.07% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.13 |
ROIC/WACCN/A
WACC8.37%
2.3 Liquidity
A Current Ratio of 1.24 indicates that CHRS should not have too much problems paying its short term obligations.
CHRS's Current ratio of 1.24 is on the low side compared to the rest of the industry. CHRS is outperformed by 85.31% of its industry peers.
A Quick Ratio of 1.23 indicates that CHRS should not have too much problems paying its short term obligations.
CHRS's Quick ratio of 1.23 is on the low side compared to the rest of the industry. CHRS is outperformed by 84.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
CHRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.27%.
Measured over the past years, CHRS shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -27.39% on average per year.
CHRS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -72.54%.
Measured over the past years, CHRS shows a decrease in Revenue. The Revenue has been decreasing by -5.60% on average per year.
EPS 1Y (TTM)-19.27%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-3200%
Revenue 1Y (TTM)-72.54%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-83.65%
3.2 Future
Based on estimates for the next years, CHRS will show a decrease in Earnings Per Share. The EPS will decrease by -4.36% on average per year.
CHRS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.39% yearly.
EPS Next Y-98.56%
EPS Next 2Y-12.58%
EPS Next 3Y-4.33%
EPS Next 5Y-4.36%
Revenue Next Year-83%
Revenue Next 2Y-46.67%
Revenue Next 3Y-27.94%
Revenue Next 5Y0.39%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CHRS. In the last year negative earnings were reported.
Also next year CHRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CHRS's earnings are expected to decrease with -4.33% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.58%
EPS Next 3Y-4.33%
5. Dividend
5.1 Amount
No dividends for CHRS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.35
-0.08 (-5.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners42.25%
Inst Owner Change-6.36%
Ins Owners6.08%
Ins Owner Change0%
Market Cap163.17M
Revenue(TTM)83.57M
Net Income(TTM)154.97M
Analysts81.82
Price Target5.1 (277.78%)
Short Float %28.38%
Short Ratio24.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.95%
Min EPS beat(2)-12.36%
Max EPS beat(2)0.45%
EPS beat(4)1
Avg EPS beat(4)-45.1%
Min EPS beat(4)-108.91%
Max EPS beat(4)0.45%
EPS beat(8)3
Avg EPS beat(8)-59.36%
EPS beat(12)6
Avg EPS beat(12)-37.23%
EPS beat(16)8
Avg EPS beat(16)-35.94%
Revenue beat(2)0
Avg Revenue beat(2)-8.12%
Min Revenue beat(2)-15.42%
Max Revenue beat(2)-0.81%
Revenue beat(4)1
Avg Revenue beat(4)-22.58%
Min Revenue beat(4)-86.37%
Max Revenue beat(4)12.3%
Revenue beat(8)3
Avg Revenue beat(8)-10.27%
Revenue beat(12)4
Avg Revenue beat(12)-11.09%
Revenue beat(16)4
Avg Revenue beat(16)-11.88%
PT rev (1m)-11.77%
PT rev (3m)-23.08%
EPS NQ rev (1m)-65.48%
EPS NQ rev (3m)-65.48%
EPS NY rev (1m)-19.18%
EPS NY rev (3m)-19.18%
Revenue NQ rev (1m)-7.08%
Revenue NQ rev (3m)-7.33%
Revenue NY rev (1m)-5.41%
Revenue NY rev (3m)-5.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.95 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.86 | ||
| P/tB | 4.26 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.3
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.69
BVpS0.73
TBVpS0.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30% | ||
| ROE | 176.56% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 185.44% | ||
| GM | 47.79% | ||
| FCFM | N/A |
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
F-Score4
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | -4.13 |
F-Score4
WACC8.37%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.27%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-3200%
EPS Next Y-98.56%
EPS Next 2Y-12.58%
EPS Next 3Y-4.33%
EPS Next 5Y-4.36%
Revenue 1Y (TTM)-72.54%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-83.65%
Revenue Next Year-83%
Revenue Next 2Y-46.67%
Revenue Next 3Y-27.94%
Revenue Next 5Y0.39%
EBIT growth 1Y-33.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-87.59%
EBIT Next 3Y12.47%
EBIT Next 5Y7.38%
FCF growth 1Y65.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.55%
OCF growth 3YN/A
OCF growth 5YN/A
COHERUS ONCOLOGY INC / CHRS FAQ
What is the ChartMill fundamental rating of COHERUS ONCOLOGY INC (CHRS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to CHRS.
Can you provide the valuation status for COHERUS ONCOLOGY INC?
ChartMill assigns a valuation rating of 0 / 10 to COHERUS ONCOLOGY INC (CHRS). This can be considered as Overvalued.
Can you provide the profitability details for COHERUS ONCOLOGY INC?
COHERUS ONCOLOGY INC (CHRS) has a profitability rating of 3 / 10.
How financially healthy is COHERUS ONCOLOGY INC?
The financial health rating of COHERUS ONCOLOGY INC (CHRS) is 2 / 10.